Covalent Group

Covalent Group was a clinical research organization (CRO) that provided a comprehensive suite of drug development services to the pharmaceutical, biotechnology, and medical device industries. The company specialized in the design, implementation, and management of Phase I through Phase IV clinical trials, with core competencies in clinical monitoring, data management, biostatistical analysis, and regulatory affairs. Headquartered in Wayne, Pennsylvania, Covalent Group was recognized for its expertise in complex therapeutic areas such as cardiovascular disease, oncology, and infectious diseases. The company was publicly traded on the NASDAQ under the symbol CVGR until its acquisition by Omnicare, Inc. in 2005 for approximately $50 million. Following the acquisition, it was integrated into Omnicare's clinical research division to expand their global service offerings.